Aigh Capital Management LLC Fennec Pharmaceuticals Inc. Transaction History

Aigh Capital Management LLC

  • $247 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$8.82 - $11.12 $2.13 Million - $2.68 Million
240,962 Added 73.16%
570,332 $6.34 Million
Q4 2023

Feb 12, 2024
SELL
$6.48 - $11.61 $286,130 - $512,651
-44,156 Reduced 11.82%
329,370 $3.7 Million
Q3 2023

Nov 13, 2023
BUY
$7.15 - $8.94 $172,093 - $215,176
24,069 Added 6.89%
373,526 $2.81 Million
Q2 2023

Aug 14, 2023
BUY
$7.27 - $9.82 $1.36 Million - $1.84 Million
187,303 Added 115.51%
349,457 $3.09 Million
Q1 2023

May 15, 2023
BUY
$7.38 - $10.35 $1.2 Million - $1.68 Million
162,154 New
162,154 $1.35 Million

Others Institutions Holding FENC

# of Institutions
64
Shares Held
14.9M
Call Options Held
10K
Put Options Held
83.8K
View Full List

About FENNEC PHARMACEUTICALS INC.

FENC Quotes by TradingView
  • Ticker FENC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,067,300
  • Market Cap $151M
  • Description
  • Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...
More about FENC
Track This Portfolio

Track Aigh Capital Management LLC Portfolio

Follow Aigh Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigh Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aigh Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email